Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2005

View Archived Issues

SCP-123: a novel intravenous analgesic

Antihyperalgesic and antidepressant effects of novel delta opioid receptor agonists

KJ-0530 shows antiinflammatory response following cerebral ischemic insult

GlaxoSmithKline: Q3 report

New Zealand scientists develop a novel hypoxic cytotoxin for tumor therapy

NCI reports on the discovery of a dual topoisomerase I/II inhibitor

Advisory Committee speaks on licensure of pneumococcal conjugate vaccines

FDA Advisory Committee recommends more data for Certican approval

Phase IIa study begins for MEM-1003 in Alzheimer's disease

StaphVAX fails to meet primary endpoint in phase III study

Novacea plans new phase III study of DN-101 in prostate cancer

Oncophage studied in phase I/II trial for glioma

Pfizer and Incyte collaborate on novel oral CCR2 antagonists

In vitro studies suggest utility of Multiferon against H5N1 avian flu virus

PRECISE trial reaches criterion for second futility statistical analysis

Merck KGaA acquires Survac

Notice of noncompliance for Marqibo in Canada

GSK-248451 classified as a potent, competitive and selective UT antagonist

Indian scientists present in vitro and in vivo data on a novel antiarthritic compound, P-979

CH-1504 shows advantages over methotrexate in advanced rheumatoid arthritis

RN-624 reduces pain due to knee osteoarthritis

AME-527 shows promise in rheumatoid arthritis patients

PEG-Uricase lowers plasma urate levels, may resolve tophi in gout patients

ATTAIN, AIM, ASSURE study data detail abatacept efficacy in rheumatoid arthritis

New treatments for cancer covered in recent patents

Novel antibacterial compounds from Prolysis

Recent patents report new therapeutic agents for metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...